Compare Cytokinetics Inc (CYTK) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Cytokinetics Inc trades at $77.58 (market cap $10.63B), while iShares 20 Plus Year Treasury Bond ETF trades at $82.34. The key difference: Cytokinetics Inc is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| CYTK | TLT | |
|---|---|---|
Market Cap | $10.63B | — |
Sector | Technology | — |
52-Week High | $87.26 | $92.06 |
52-Week Low | $34.31 | $82.05 |
Enterprise Value | $10.74B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $82.40, up 0.43% on the day, amid a bearish technical signal with selling pressure dominating moving averages. Recent news highlights rising Treasury yields and inflation concerns, with institutional buying noted. The ETF provides exposure to long-term U.S. government bonds, with dividend distributions continuing regularly.
Outlook remains cautious due to interest rate uncertainty and inflation pressures, offering income but facing headwinds from potential Fed policy shifts. Key risks include yield volatility and macroeconomic factors impacting bond prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
